Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pomalidomide · 1 trial · 1 indication
PFS is defined as the time in days from subject randomization to the date of the first documented progressive disease (PD) or death due to any cause, whichever occurs first.
| Arm | Type | Description |
|---|---|---|
| Arm 1 VenDex | EXPERIMENTAL | Venetoclax administered orally once daily (QD) plus dexamethasone administered orally once every week (Q1W) for each 28-day cycle. |
| Arm 2 PomDex | ACTIVE_COMPARATOR | Pomalidomide administered orally once daily (QD) on Days 1 - 21 for each 28-day cycle plus dexamethasone administered orally once every week (Q1W) for each 28-day cycle. |
| Name | Type | Description |
|---|---|---|
| Pomalidomide | DRUG | capsule, oral |
| Dexamethasone | DRUG | oral, locally available form |
| Venetoclax | DRUG | tablet; oral |
Inclusion Criteria: * Documented diagnosis of multiple myeloma (MM) based on standard International Myeloma Working Group (IMWG) criteria. * Measurable disease at screening as defined per protocol. * Has received at least 2 prior lines of therapy as described in the protocol. * Has had documented d...
Top 20 of 26 competitors